• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Targeting 5alpha-reductase for prostate cancer prevention and treatment.
【24h】

Targeting 5alpha-reductase for prostate cancer prevention and treatment.

机译：靶向5α-还原酶用于前列腺癌的预防和治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Testosterone is the most abundant circulating androgen, and can be converted to dihydrotestosterone (DHT), a more potent androgen, by the 5alpha-reductase enzymes in target tissues. Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR). Although these therapies reduce tumor burden and AR activity, the cancer inevitably recurs within 18-30 months. An approach targeting the androgen-AR axis at different levels could, therefore, improve the efficacy of prostate cancer therapy. Inhibition of 5alpha-reductase is one such approach; however, the two largest trials to investigate the use of the 5alpha-reductase inhibitors (5ARIs) finasteride and dutasteride in patients with prostate cancer have shown that, although the incidence of cancer was reduced by 5ARI treatment, those cancers that were detected were more aggressive than in patients treated with placebo. Thus, the best practice for using these drugs to prevent and treat prostate cancer remains unclear.
机译：睾丸激素是循环中最丰富的雄激素，可通过靶组织中的5alpha-还原酶将其转化为更有效的雄激素二氢睾丸激素（DHT）。当前用于前列腺癌的治疗包括通过化学或手术去势或直接靶向雄激素受体（AR）的纯抗雄激素疗法降低雄激素水平。尽管这些疗法减轻了肿瘤负担和AR活性，但癌症不可避免地会在18-30个月内复发。因此，针对雄激素-AR轴的水平不同的方法可以提高前列腺癌治疗的功效。抑制5α-还原酶就是这样一种方法。然而，两项最大的研究对前列腺癌患者使用5alpha-还原酶抑制剂（5ARIs）的非那雄胺和度他雄胺的研究表明，尽管通过5ARI治疗降低了癌症的发生率，但发现的那些癌症更具侵略性比接受安慰剂治疗的患者要多。因此，使用这些药物预防和治疗前列腺癌的最佳实践尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号